Biogen Reports Phase 2b Data for Trastuzumab deruxtecan in Gastric cancer

Biogen today announced Phase 2b results for trastuzumab deruxtecan in patients with gastric cancer. The study demonstrated that trastuzumab deruxtecan improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of gastric cancer and support the continued development of trastuzumab deruxtecan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.